Implementing a personalized medicine cancer program in a community cancer system

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Schilsky RL. Implementing personalized cancer care. Nat. Rev. Clin. Oncol. 11(7), 432–438 (2014).•• Dr Schilsky is the Chief Medical Office of the American Society for Clinical Oncology (ASCO) and the former head of the National Cancer Institute (NCI) sponsored cooperative oncology group, the Cancer and Leukemia Group B. He presents an overview of ASCO's position and personalized cancer care, including a blueprint for the future.
  MedlineGoogle Scholar
• 2. Nadauld LD, Ford JM, Pritchard D, Brown T. Strategies for clinical implementation: precision oncology at three distinct institutions. Health Aff. 37(5), 751–756 (2018).
  Google Scholar
• 3. National Comprehensive Cancer Network (2018). Non-Small Cell Lung Cancer Version 3.2018 – February 21, 2018. www.nccn.org/thoracic
  Google Scholar
• 4. National Comprehensive Cancer Network. (2018). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer Version 2.2018-March 14, 2018. www.nccn.org/colorectal
  Google Scholar
• 5. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a personalized medicine infrastructure at a major cancer center. J. Clin. Oncol. 31(15), 1849–1857 (2013).
  MedlineGoogle Scholar
• 6. Dressler LG, Deal AM, Owzar K et al. Participation in cancer pharmacogenomic studies: a study of 8456 patients registered to clinical trials in the cancer and leukemia group B (alliance). J. Nat. Cancer Inst. 107(10), pii: djv188 (2015).
  MedlineGoogle Scholar
• 7. Dalton WB, Forde PM, Kang H et al. Personalized Medicine in the oncology clinic: implementation and outcomes of the John Hopkins molecular tumor board. JCO Precis. Oncol. 46(1), 1–19 (2017).
  Google Scholar
• 8. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 17(6), 528–536 (2011).
  MedlineGoogle Scholar
• 9. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 12(5), 358–369 (2013).
  Medline CASGoogle Scholar
• 10. Thompson MA, Godden JJ, Weissman SM et al. Implementing an oncology precision medicine clinic in a large community health system. Am. J. Manag. Care 23(10 Spec No.), SP425–SP427 (2017).
  MedlineGoogle Scholar
• 11. Knepper TC, Bell GC, Hicks JK et al. Key lessons learned from Moffitt's molecular tumor board: the clinical genomics action committee experience. Oncologist 22(2), 144–151 (2017). • Describes the development of a molecular tumor board including the provision of a consultative report or summary of findings from comprehensive genomic profiling. The information provided can be adapted by other sites.
  MedlineGoogle Scholar
• 12. American Society of Clinical Oncology (ASCO). The State of Cancer Care in America, 2017: a report by the American Society of Clinical Oncology. J. Oncol. Pract. 13(4), 256–394 (2017). •• This annual report from the ASCO (the largest clinical cancer professional group in the world) puts into context the environmental, geographical, clinical, cultural and financial issues affecting the delivery of cancer care in USA.
  Google Scholar
• 13. Kean MP, Pritchard, D. Emerging models for clinical adoption of personalized medicine. J. Pers. Med. 4, 52–65 (2017).• Reviews several institutions' approach to adopting and implementing personalized medicine, including lessons learned and common threads.
  Google Scholar
• 14. Harris LN, Ismaila N, Mcshane LM, Hayes DF. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline summary. J. Oncol. Pract. 12(4), 384–389 (2016).
  MedlineGoogle Scholar
• 15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. (2017). www.nccn.org/riskassessment/colorectal Genetic/Familial High-Risk Assessment: Colorectal Version 3.2017-October 10,2017.
  Google Scholar
• 16. Cragun D, Debate RD, Vadaparampil ST, Baldwin J, Hampel H, Pal T. Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. Genet. Med. 16(10), 773–782 (2014).
  MedlineGoogle Scholar
• 17. Stoffel EM, Mangu PB, Limburg PJ. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. J. Oncol. Pract. 11(3), e437–e441 (2015).
  MedlineGoogle Scholar
• 18. Glasgow RE, Vinson C, Chambers D, Khoury MJ, Kaplan RM, Hunter C. National Institutes of Health approaches to dissemination and implementation science: current and future directions. Am. J. Public Health 102(7), 1274–1281 (2012).
  MedlineGoogle Scholar
• 19. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement. Sci. 4(50) doi.org/10.1186/1748-5908-4-50. (2009). • A comprehensive discussion illustrating how a framework for advancing implementation science can be applied to different settings and datasets.
  MedlineGoogle Scholar
• 20. Rogers E. Diffusion of Innovations. (4th Edition). The Free Press, NY, USA, 10–35 (1995).
  Google Scholar
• 21. Brown TD. Role of community-based genomics programs. JCO Precis. Oncol. 106(1), 1–3 (2017).
  Google Scholar
• 22. Burkard ME, Deming DA, Parsons BM et al. Implementation and clinical utility of an integrated academic-community regional molecular tumor board. JCO Precis. Oncol. 22(1), 1–10 (2017).
  Google Scholar